PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Oral Step-Down for Gram-Negative Bacteremia Survives Confounding Adjustment

oral step-downGram-negative bloodstream infectionEnterobacteralesfluoroquinolonesoral beta-lactamstrimethoprim-sulfamethoxazoleIV-to-oral switchantimicrobial stewardshipmeta-analysisbacteremiaE. coliKlebsiella Infectious Disease / Antimicrobials

Background Information

Oral antibiotics may safely replace IVs for Gram-negative BSIs.

Optimizing antimicrobial use in Gram-negative bloodstream infections (BSIs) can reduce complications and healthcare costs. Oral step-down therapy showed lower all-cause mortality (RR: 0.39) and less microbiological failure (RR: 0.69) compared to continued intravenous (IV) therapy. The findings support switching to oral antibiotics within 5 days for certain patients with Gram-negative BSIs, though differences were not significant in rigorous sensitivity analyses. Oral step-down therapy for Gram-negative BSIs is effective and reduces IV exposure without worsening outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Onorato L, De Luca I, Ferrante M, Ricciardiello G, Monari C, Coppola N

Citation: Onorato L, De Luca I, Ferrante M, et al. Oral Stepdown Therapy for Gram-Negative Bloodstream Infections: A Systematic Review and Meta-Analysis. European journal of clinical investigation. 2026;56(8):e70244. doi:10.1111/eci.70244

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →